BridgeMD
New treatment option for Septic Shock
Official title Early Angiotensin II in the Emergency Department
ClinicalTrials.gov ID: NCT06693726
What this study is testing
What is Angiotensin II Infusion?
Angiotensin II Infusion is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for septic shock.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Age ≥18; and
- Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
- Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
- Can provide written informed consent (or legally authorized representative).
You likely can't join if
- Acute coronary syndrome;
- Cardiogenic shock;
- Patients with a history of mesenteric ischemia;
- Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
- Patients with an expected lifespan of \<12 hours;
- Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
See the full eligibility criteria
- Age ≥18; and
- Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
- Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
- Can provide written informed consent (or legally authorized representative).
- Acute coronary syndrome;
- Cardiogenic shock;
- Patients with a history of mesenteric ischemia;
- Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
- Patients with an expected lifespan of \<12 hours;
- Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
- Active administration of two vasoactive agents before enrollment; and
- Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.
The study team makes the final eligibility decision.
Where it's taking place
- Iowa City, Iowa, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Iowa City, Iowa, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.